Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VGR-R01 in the Contralateral Eye for Bietti's Crystalline Dystrophy
NCT07586306Phase 2Not yet recruiting
- Sponsor
- Shanghai Vitalgen BioPharma Co., Ltd.
- Start
- Jun 2026
- Primary completion
- Jul 2027
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of VGR-R01 in Bietti crystalline dystrophy (BCD), sponsored by Shanghai Vitalgen BioPharma Co., Ltd.. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
VGR-R01
03
Conditions
Bietti crystalline dystrophy (BCD)
Beyond the preview
Go deeper on NCT07586306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07586306.